- Celyades Oncology CYAD offers an update on its Celyad 2.0 business strategy, which has been adopted and implemented in recent months.
- The company has assembled a fundamental and broad IP fortune.
- In addition to IP partnering transactions, Celyad 2.0 will prioritize discovery research in the following areas:
- Multiplexing approach of the short hairpin RNA (shRNA) platform.
- Dual-CAR development of a next-generation NKG2D-based CAR.
- Development of B7-H6 targeted immunotherapies for multiple cancer types.
- Celyad has decided to discontinue development of its remaining clinical program, CYAD-211 (the allogeneic shRNA-based anti-BCMA CAR T candidate for relapsed or refractory multiple myeloma).
- No safety concerns led to this decision, and all patients previously treated with CYAD-211 will continue to receive their protocol-defined follow-up.
- In its third quarter earnings release, the Company decided to discontinue development of CYAD-101 following previously announced actions clinical hold resolution.
- The Company will provide information on the potential proof-of-concept dual CAR and multiplexing research programs and business development in Q2 2023.
- Price promotion: CYAD shares are down 34.72% to $0.6789 during the pre-market session last check Wednesday.
- Photo via company
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
